Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Asahi Kasei Pharma Corporation Patents
Assignee:
Asahi Kasei Pharma Corporation
Address:
Tokyo, JP
No. of patents:
50
Patents:












Patent Number Title Of Patent Date Issued
8299055 8-substituted isoquinoline derivative and the use thereof October 30, 2012
The present invention relates to a compound represented by the following formula (1): ##STR00001## wherein D.sup.1, A.sup.1, D.sup.2, R.sup.1, D.sup.3, and R.sup.2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the form
8268017 Method for stabilizing leuco-type colorant September 18, 2012
Provided are a method of stabilizing a leuco dye storable as a liquid for a long time, a method of reducing nonspecific color development thereof at a time of a color development reaction, and a stable liquid reagent composition using the methods. The inventors of the present invention
8258269 Method for producing high-purity soluble thrombomodulin September 4, 2012
It is an object of the present invention to obtain a soluble thrombomodulin substantially not containing a denatured product of soluble thrombomodulin that may be generated under acidic conditions. The present invention provides a method for producing soluble thrombomodulin substanti
8232292 Sulfonamide compound and crystal thereof July 31, 2012
(S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2.theta.s are
8105800 Composition for assaying glycated proteins January 31, 2012
Composition for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) siabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the e
8105766 Method of measuring pyrophosphate January 31, 2012
Provided is a novel and useful method of measuring pyrophosphate in a sample. There may be provided a novel and useful method of measuring pyrophosphate in a sample using pyruvate orthophosphate dikinase, nicotinamide-nucleotide adenylyltransferase, and dehydrogenase.
8080423 Reagent containing protease reaction promoter and/or colorant stabilizer December 20, 2011
Stabilizers for colorants used for detection of enzymatic reactions, having a cyclodextrin and a catalase; reagents including stabilizers; and methods of use of such stabilizers and reagents.
8053409 Agent for prophylaxis of reflex sympathetic dystrophy after cerebral apoplexy November 8, 2011
The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active
8039514 Sulfonamide compounds and use thereof October 18, 2011
The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promo
8026075 Method for stabilizing coenzyme and composition thereof September 27, 2011
Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphoryla
8008506 Indazole compounds August 30, 2011
Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have .beta.3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes
7994202 Bicyclic nitrogen-containing heterocyclic compounds August 9, 2011
A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, a
7973030 Benzothiazepine and benzothiepine compounds July 5, 2011
A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangi
7964613 Sulfonamide compound June 21, 2011
A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G.sup.1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G.sup.2 represents a h
7960392 Nitrogen-containing heterocyclic compounds June 14, 2011
Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical
7943337 Method for screening a protease May 17, 2011
There is provided a method for specifically determining a glycated .beta.-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a gly
7935720 Crystal of substituted phenylalkanoic acid ester and process for producing the same May 3, 2011
In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionat- e, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionat- e as a
7919460 Method for prophylaxis of reflex sympathetic dystrophy after stroke April 5, 2011
The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active
7893050 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension February 22, 2011
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations
7883862 Diglyceride solutions for lipase activity determination February 8, 2011
Diglyceride solutions for lipase activity determination, comprising at least one diglyceride, a low concentration buffer, and a nonionic surfactant.
7879567 Method for stabilizing coenzyme and composition therefor February 1, 2011
Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphoryla
7838546 Crystal of substituted phenylalkanoic acid ester and process for producing the same November 23, 2010
In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionat- e, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionat- e as a
7803792 Quaternary ammonium compounds September 28, 2010
A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1): ##STR00001##
7754752 Crystals of substituted phenylalkanoic acid and method of producing the same July 13, 2010
In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionat- e, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionat- e as a
7718797 Fasudil-containing preparation and method of improving stability thereof May 18, 2010
Fasudil-containing preparations that despite the us of a container excelling in the visibility of contents without particularly blocking of light, exhibit high stability against light; and a method of improving the stability of the preparations against light of storing the same. By r
7629453 NF-.kappa.B activating gene December 8, 2009
Provided are proteins having NF-.kappa.B activity, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-.kappa.B. Using plasmid pNF .kappa.B-Luc, cDNA encoding a protein capable of activating NF-.kappa.B has been clon
7618984 Sulfonamide compound November 17, 2009
A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G.sup.1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G.sup.2 represents a h
7598284 Indazole compounds as B3 adrenoceptor agonist October 6, 2009
Compounds of the general formula (I): ##STR00001## or a salt thereof, wherein R.sup.1 is a hydrogen atom or the like; R.sup.2 is NHSO.sub.2R.sup.3 or the like; R.sup.3 is a (C.sub.1-C.sub.6)alkyl group or the like; R.sup.5 is a hydrogen atom or the like; R.sup.6 and R.sup.7 may be t
7588910 Hemoglobin A1c determination method, enzyme to be used therefor, and production method thereof September 15, 2009
There is provided a method for specifically determining a glycated .beta.-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a gly
7582658 Bicyclic compound September 1, 2009
A novel compound represented by the following formula (1) or a salt thereof: ##STR00001## wherein symbol "A" represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R.sup.2, R.sup.3, and
7560478 Crystal forms of substituted phenylalkanoic acids and process for producing the same July 14, 2009
In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionat- e, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionat- e as a
7531533 6-Membered heterocyclic compound and use thereof May 12, 2009
A compound represented by the general formula (I) or a salt thereof: ##STR00001## [T represents oxygen atom and the like; V represents CH.sub.2 and the like; R.sup.01 to R.sup.04 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group ha
7470807 Substituted arylalkanoic acid derivatives and use thereof December 30, 2008
A compound represented by the formula (I): ##STR00001## [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C.sup.2 to C.sup.6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the
7452687 Method of detecting mild impaired glucose tolerance or insulin secretory defect November 18, 2008
It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or hyposecretion at the early stage are detected by quantifying
7312208 Quaternary ammonium compounds December 25, 2007
Drugs useful for the treatment and prevention of hyperlipidemia, moreover drugs useful for the treatment and prevention of cholestasis-caused hepatopathy, particularly primary biliary cirrhosis and primary sclerosing cholangitis, and drugs for the treatment and prevention of obesity,
7271190 Indazole compounds as .beta.3 adrenoceptor agonist September 18, 2007
A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R.sup.2 represents NHSO.sub.2R.sup.3, etc., provided that R.sup.3 represents C.sub.1-6 alkyl, etc. R.sup.5 represents hydrogen, etc. R.sup.6 and R.sup.7 may be the same or different and each indep
7250269 Composition for assaying glycoprotein July 31, 2007
Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) siabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the
7227007 NF-.kappa.B activating gene June 5, 2007
Provided are proteins having NF-.kappa.B activity, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-.kappa.B. Using plasmid pNF.kappa.B-Luc, cDNA encoding a protein capable of activating NF-.kappa.B has been clone
7160894 Tricyclic compound January 9, 2007
A novel compound represented by the formula (1): ##STR00001## [R.sup.1 represents hydrogen atom, chlorine atom, or hydroxyl group; X.sup.1 . . . X.sup.2 represents--CH(R.sup.2)--CH(R.sup.3)--, --CH(R.sup.2)--CH(R.sup.3)--CH(R.sup.4)--, etc.; R.sup.2 to R.sup.4represent hydrogen atom
7125567 Process for producing an oral sustained-release preparation of fasudil hydrochloride October 24, 2006
Disclosed is an oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof, the preparation comprising at least one sustained-release coated particle comprising a core having a surface
7094789 5-substituted isoquinoline derivatives August 22, 2006
A compound represented by the following formula (1) or a salt thereof: ##STR00001## wherein R.sup.1 represents hydrogen atom, a halogen atom and the like; R.sup.2 represents hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group and the like; and R.sup.3 represents --O--X--C(A.sup.1
7049445 Bicyclic compounds May 23, 2006
Compounds of the general formula (I): ##STR00001## or a salt thereof, wherein R.sup.1 is hydrogen, hydroxyl or halogen; R.sup.2 is NHSO.sub.2CH.sub.3, SO.sub.2NHCH.sub.3 or the like; R.sup.5 and R.sup.6 each independently is hydrogen, C.sub.1-6 alkyl, optionally substituted phenyl
7015345 Propionic acid derivatives March 21, 2006
A compound represented by the following formula (1) or a salt thereof: ##STR00001## wherein R.sup.1 represents a C.sub.1-12 alkyl group, phenyl group, 1-naphthyl group and the like, R.sup.2 represents a C.sub.2-12 alkyl group, (R.sup.3).sub.b represents 0 to 4 substituents such as a
6887820 Method for producing optically active compounds May 3, 2005
A method for producing optically active compounds is disclosed. The method is highly practical for producing optically active compounds useful for various utilities such as intermediates for synthesizing pharmaceutical agents, liquid crystal materials and agents for optical resolution.
6867320 Substituted phenylalkanoic acid derivatives and use thereof March 15, 2005
A compound represented by the formula (I) or a salt thereof: ##STR1##wherein n represents an integer of 1 to 3, R represents an alkyl group having 3 to 8 carbon atoms, a group represented by the following formula: R.sup.1 (CH.sub.2).sub.k -- (wherein k represents 0 or an integer of 1 to
6861444 Bicyclic compounds March 1, 2005
Compounds of the general formula (I): ##STR1##or a salt thereof, wherein R.sup.1 is hydrogen, hydroxyl or halogen; R.sup.2 is NHSO.sub.2 CH.sub.3, SO.sub.2 NHCH.sub.3 or the like; R.sup.5 and R.sup.6 each independently is hydrogen, C.sub.1-6 alkyl, optionally substituted phenyl or op
6797169 Filter membranes for physiologically active substances September 28, 2004
Filter membranes for efficiently eliminating pathogens such as viruses from solutions of drugs or physiologically active substances employed as starting materials thereof which are contaminated with pathogens such as viruses. These filter membranes, which can simultaneously achieve f
6706683 Method for controlling the release of granules March 16, 2004
A method of controlling granule secretion comprising performing a treatment to increase or decrease an active form of calgranulin on a cell line having capability of secreting granules, thereby increasing or decreasing granule secretion from the cell line.A method of detecting a substanc
6699508 Sustained release oral preparations of fasudil hydrochloride March 2, 2004
An oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof is disclosed. A method for evaluating an oral sustained-release preparation containing the active ingredient, wherein
6696266 Method for assaying ammonia using an NAD-based cycling reaction system February 24, 2004
A method for assaying ammonia and/or ammonium ions contained in a liquid sample which comprises subjecting the sample to a reaction at least in the presence of an NAD synthetase, deamidated NAD, ATP, Mg.sup.2+ ions and/or Mn.sup.2+ ions, a dehydrogenase capable of forming ammonia molecul

 
 
  Recently Added Patents
Humidity indicator and method for fabricating the same
Method of optimizing air mover performance characteristics to minimize temperature variations in a computing system enclosure
Image forming apparatus with an improved density adjustment unit
Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
Method for using a super-slippery thin layer characterized by the method for making same
Rapid glycopeptide optimization via neoglycosylation
Software self-checking systems and methods
  Randomly Featured Patents
Database backup system ensuring consistency between primary and mirrored backup database copies despite backup interruption
Configurable memory system with interface circuit
Compact terminal assembly for power converters
Extracting information from unstructured data and mapping the information to a structured schema using the naive bayesian probability model
Collapse preventing connection device for building structures
Gaming machine
Faucet handle
Ladder type band-pass filter comprising of assembled plural vibrator blocks
Fitted sheet
Semiconductor power switch system